![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with folfirinox-based therapies for pancreatic, colon, and appendiceal cancers.
Lead Product(s): Certepetide,Panitumumab
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2024
Details:
Data showed that combining LUMAKRAS®/LUMYKRAS® (sotorasib) with Vectibix® (panitumumab), Amgen's monoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody, demonstrated encouraging efficacy and safety.
Lead Product(s): Sotorasib,Panitumumab
Therapeutic Area: Oncology Product Name: Lumakras
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
The results of trial showed that mFOLFOX6 + Vectibix (Panitumumab) combination provides a statistically significant improvement in OS over mFOLFOX6 + bevacizumab combination in patients with a left-sided primary tumor or regardless of tumor locations.
Lead Product(s): Panitumumab,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: Vectibix
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
New data support initiation of Phase 3 trial of LUMAKRAS plus Vectibix in patients with 3L+ KRAS G12C-mutated advanced colorectal cancer (CRC). 9.7% response rate observed with LUMAKRAS monotherapy and highlight the importance of combination therapy in CodeBreaK 101 data.
Lead Product(s): Sotorasib,Panitumumab
Therapeutic Area: Oncology Product Name: Lumakras
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021